Navigation Links
InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
Date:1/8/2009

LOS ALTOS, Calif., Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference.

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease. The company's lead program is INT131, a late-stage non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator). INT131 is the result of an extensive molecular design effort to address the problematic safety concerns of TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from these serious TZD side effects.

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely reduce insulin resistance, addressing an important unmet medical need.

InteKrin expects to complete enrollment of its 360 patient, 24-week, placebo-controlled Phase 2b study of INT131 at four doses compared to 45mg Actos in
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
4. Horizon Therapeutics Announces Senior Management Appointments
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Custom Computer Specialists, ... today that they are silver sponsors of the Primary ... PCDC sponsor, Custom is lending their support of PCDC,s ... communities. Since its founding in 1993, PCDC ... primary care area.  PCDC has financed over 100 completed ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter ... — a revolutionary new archwire that allows orthodontists to simultaneously apply different forces ... the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer to ...
(Date:6/29/2015)... and Manhattan, KS (PRWEB) , ... June 29, ... ... acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will ... Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a ...
(Date:6/29/2015)... June 29, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... "Pete" Petit, has been awarded the Lifetime Achievement Award ... Program. The Entrepreneur Of The Year ...
Breaking Biology Technology:Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx 2
... ... ,For Excellence In The International Marketplace. , ... (PRWEB) March 24, 2010 -- Sterlitech Corporation, one of the ... acceptance of the prestigious Faces of Trade® Award presented by the US Chamber of ...
... , ... , ... ... NEW YORK , March 23 The Michael J. Fox Foundation announced that monoclonal ...
... Qteros, Inc., and the University of Massachusetts Amherst announced today that the ... Producing Biofuels and Related Materials" describing the novel creation of products, including biofuels, through the fermentation ... ... ...
Cached Biology Technology:US Chamber Of Commerce Honors Sterlitech Corporation 2Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 2Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 3Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development 4Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 2Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 3Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 4Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 5Qteros and UMass Amherst Announce the Issuance of a U.S. Patent for Production of Ethanol From a Unique Microorganism, the Q Microbe(TM) 6
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
(Date:6/17/2015)... Fla. , June 17, 2015  Crossmatch™, ... today announced that its U.are.U ® 4500 ... Togo,s Eateries, Inc., a ... sandwich chain, to increase security, improve accountability and ... readers enable instant, non-repudiable identity confirmation for employee ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... New research shows that following a vegetarian diet and ... risk of diabetes in African Americans, who are twice as ... whites. "These findings are encouraging for preventing ... susceptible to the disease than other populations," said Serena Tonstad, ...
... York, November 3, 2011 Impulsive individuals tend ... drug and alcohol abuse, to problem gambling and difficult ... social situations. Impulsivity is also a common feature of ... shows that people may react this way, in part, ...
... which people use before progressing to the use of ... this progression is called the "gateway sequence" of drug ... by Amir Levine, MD, Denise Kandel, PhD; Eric Kandel, ... the first molecular explanation for the gateway sequence. They ...
Cached Biology News:Vegetarian diet, physical activity protect against diabetes in black population, study shows 2Impulsive versus controlled men: Disinhibited brains and disinhibited behavior 2Nicotine primes brain for cocaine use: Molecular basis of gateway sequence of drug use 2
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
...
... array sample elements. , , ,Includes:, , , ... PBS (10X): 50 ml , INDIA HisProbe HRP: 0.2 ... 10% Tween-20: 2 x 10 ml ampules , SuperSignal ... SuperSignal West Pico Stable Peroxide: 2 x 25 ...
Biology Products: